Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Theodore Brown

Physical Medicine & Rehabilitation Kirkland, WA Medical Doctor

NPI 1568416873 CMS profile 70970

12039 Ne 128Th St, Suite 300, Kirkland, WA 98034

Open in the dashboard

General payments

$61,764

322 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$4,436,137 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Theodore Brown of Kirkland, WA is reported in the CMS Open Payments database as having received $61,764 across 322 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $4,436,137 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 98th percentile of Physical Medicine & Rehabilitation profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,689 60
2024 General $7,227 62
2023 General $1,065 40
2022 General $15,338 68
2021 General $7,021 43
2020 General $8,436 24
2019 General $20,989 25

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Theodore Brown
  • Physical Medicine & Rehabilitation median
  • Middle half of Physical Medicine & Rehabilitation
  • National median

In program year 2025, general payments to Theodore Brown were reported at $1,689. Among 4,146 Physical Medicine & Rehabilitation profiles paid that year, the median was $139 and the middle half received between $48 and $410.

Show as a table
Year Theodore Brown Physical Medicine & Rehabilitation median Middle half National median
2019 $20,989 $133 $45–$390 $163
2020 $8,436 $88 $29–$272 $114
2021 $7,021 $116 $33–$360 $132
2022 $15,338 $123 $40–$378 $149
2023 $1,065 $131 $43–$396 $160
2024 $7,227 $141 $45–$409 $164
2025 $1,689 $139 $48–$410 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. E.R. Squibb & Sons, L.L.C. $12,865 11 payments
  2. Celgene Corporation $11,929 62 payments
  3. Genzyme Corporation $9,051 14 payments
  4. Novartis Pharmaceuticals Corporation $7,949 40 payments
  5. Merck KGaA $7,014 2 payments
  6. Greenwich Biosciences, Inc. $6,590 9 payments
  7. EMD Serono, Inc. $1,964 18 payments
  8. TG Therapeutics, Inc. $1,047 31 payments
  9. AbbVie, Inc. $607 22 payments
  10. Merz Pharmaceuticals, LLC $534 19 payments
  11. Other $2,214 94 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $42,194 20 payments
  2. Consulting Fee $8,509 3 payments
  3. Food and Beverage $7,037 275 payments
  4. Travel and Lodging $3,571 15 payments
  5. Education $454 9 payments
Products named General payments · program years 2019–2025
  1. ZEPOSIA $11,984 65 payments
  2. Mavenclad Neurodegenerative Diseases $7,014 2 payments
  3. Epidiolex $6,621 11 payments
  4. Mavenclad Neurology $1,200 1 payment
  5. BRIUMVI $1,047 31 payments
  6. KESIMPTA Neurology $368 14 payments
  7. AUBAGIO $340 8 payments
  8. Xeomin musculoskeletal $327 11 payments
  9. KESIMPTA Neuroscience $279 14 payments
  10. Xeomin musculoskeletal $211 8 payments
  11. Other $3,350 141 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 59 drugs

Part D claims

2,348

Median for Physical Medicine and Rehabilitation: 276

Drug cost

$1,127,978

Median for Physical Medicine and Rehabilitation: $5,921

Branded share of claims

22.9%

Median for Physical Medicine and Rehabilitation: 11.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Copaxone Glatiramer Acetate Brand 38 $214,952
Glatiramer Acetate Generic 45 $167,846
Glatopa Glatiramer Acetate Brand 48 $163,558
Teriflunomide Generic 51 $103,104
Avonex Pen (4 Pack) Interferon Beta-1a Brand 12 $98,674
Avonex (4 Pack) Interferon Beta-1a Brand 11 $89,866
Bafiertam Monomethyl Fumarate Brand 13 $83,627
Fingolimod Fingolimod Hcl Brand 47 $78,215
Dalfampridine Er Dalfampridine Brand 86 $30,173
Dimethyl Fumarate Generic 96 $27,896

The 10 drugs with the highest cost, of 59 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 7,591 Part D prescribers listed as Physical Medicine and Rehabilitation; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 16 billing codes

Paid by Medicare

$25,970

Medicare's payments for the services billed

Medicare patients

132

Average age 67

Services billed

462

98 women, 34 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 53%
Depression 40%
Arthritis 39%
Osteoporosis 36%
Diabetes 18%
Chronic kidney disease 16%
Ischemic heart disease 13%
Heart failure 9%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 25 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
BRIUMVI
  • TG Therapeutics, Inc. $281
$281 — —
ZEPOSIA
  • Celgene Corporation $148
$148 — —
Xeomin
  • Merz Pharmaceuticals, LLC $92
$92 — —
Austedo XR
  • Teva Pharmaceuticals USA, Inc. $90
$90 — —
NUPLAZID
  • ACADIA Pharmaceuticals Inc $76
$76 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 25 in the dashboard with a free account

Records

322 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physical Medicine & Rehabilitation in Washington

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record